Ionis Pharmaceuticals, Inc. (IONS) has a negative trailing P/E of -32.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 65.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.11%, forward earnings yield 1.52%. PEG 0.51 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -95.7 | 35.39 | 58.03 | 15.50 | - |
| 2017 | 18,028.9 | -193.20 | 22.20 | 12.13 | - |
| 2018 | 26.1 | -0.01 | 6.83 | 11.93 | - |
| 2019 | 30.4 | 20.98 | 5.75 | 7.53 | - |
| 2020 | -17.8 | 0.07 | 10.62 | 10.82 | - |
| 2021 | -150.1 | 1.60 | 5.56 | 5.29 | - |
| 2022 | -19.9 | -0.02 | 9.35 | 9.12 | - |
| 2023 | -19.8 | -0.57 | 18.71 | 9.18 | - |
| 2024 | -11.5 | -0.61 | 8.88 | 7.41 | - |
| 2025 | -33.2 | 1.53 | 25.88 | 13.41 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.72 | $346.62M | $-86.56M | -25% |
| 2017 | $-0.05 | $507.67M | $-5.97M | -1.2% |
| 2018 | $2.04 | $599.67M | $273.74M | 45.6% |
| 2019 | $2.06 | $1.12B | $294M | 26.2% |
| 2020 | $-3.49 | $729M | $-487M | -66.8% |
| 2021 | $-0.21 | $810M | $-29M | -3.6% |
| 2022 | $-1.90 | $587M | $-270M | -46% |
| 2023 | $-2.56 | $787.65M | $-366.29M | -46.5% |
| 2024 | $-3.04 | $705.14M | $-453.9M | -64.4% |
| 2025 | $-2.38 | $944M | $-381M | -40.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.98 | $-4.94 – $-2.14 | $821.46M | $739.06M – $1.08B | 8 |
| 2027 | $-1.15 | $-6.37 – $4.55 | $1.44B | $1.05B – $1.6B | 9 |
| 2028 | $1.17 | $-5.70 – $7.60 | $1.98B | $1.97B – $2B | 10 |
| 2029 | $3.29 | $2.39 – $4.12 | $2.76B | $2.18B – $3.3B | 4 |
| 2030 | $6.13 | $4.45 – $7.68 | $3.57B | $2.82B – $4.27B | 4 |
